Growth inhibitory effects of sodium phenylacetate (NSC 3039) on ovarian carcinoma cells in vitro

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4309-4315

  Ferrandina, Gabriella ^a,b   Melichar, Bohuslav ^a   Loercher, Amy ^a   Verschraegen, Claire F ^a   Kudelka, Andrzej P ^a   Edwards, Creighton L ^a   Scambia, Giovanni ^b   Kavanagh, John J ^a   Abbruzzese, James L ^a   Freedman, Ralph S ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; HLA ANTIGEN CLASS 1; NSC 3039; PHENYLACETATE SODIUM; PHENYLACETIC ACID DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES FLUID; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG MIXTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH INHIBITORS; HUMANS; OVARIAN NEOPLASMS; PHENYLACETATES; TUMOR CELLS, CULTURED;

EID: 0030804303     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. Cancer statistics, 1997. CA Cancer J. Clin. 47: 5-28, 1997.
2. Copeland, L. J., and Gershenson, D. M. Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy. Obstet. Gynecol., 68: 873-874, 1986.
3. Sandler, M., Ruthven, C. R. J., Goodwin, B. L., Less, A., and Stern, G. M. Phenylacetic acid in human body fluids: high correlation between plasma and cerebrospinal fluid concentrations values. J. Neurol. Neurosurg. Psychiatry, 45: 366-368, 1982.
4. Samid, D., Shack, S., and Sherman, L. T. Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res., 52: 1988-1992, 1992.
5. Samid, D., Yeh, A., and Prasanna, P. Induction of erythroid differentiation and fetal hemoglobin production in human leukemic cells treated with phenylacetate. Blood, 80: 1576-1581, 1992.
6. Cinatl, J. J., Cinatl, J., Mainke, M., Weibflog, A., Rabenau, H., Kornmhuber, B., and Doerr, H. W. In vitro differentiation of human neuroblastoma cells induced by sodium phenylacetate. Cancer Lett., 70: 41-48, 1993.
7. Cinatl, J., Cinatl, J., Herneiz, P., Rabenau, H., Novak, M., Benda, R., Gümbel, H., Kornhuber, B., and Doerr, H-W. Induction of myogenic differentiation in a human rhabdomyosarcoma cell line by phenylacetate. Cancer Lett., 78: 41-48, 1994.
8. Sidell, N., Wada, R., Han, G., Chang, B., Shack, S., Moore, T., and Samid, D. Phenylacetate synergizes with retinoic acid in inducing the differentiation of human neuroblastoma cells. Int. J. Cancer, 60: 507-514, 1995.
9. Adam, L., Crepin, M., Savin, C., and Israel, L. Sodium phenylacetate induces growth inhibition and Bcl-1 down-regulation and apoptosis in MCF7 ras cells in vitro and in nude mice. Cancer Res., 55: 5156-5160, 1995.
10. Ram, Z., Samid, D., Walbridge, S., Oshiro, E. M., Viola, J. J., Tao-Cheng, J-H., Shack, S., Thibault, A., Myers, C. E., and Oldfield, E. H. Growth inhibition, tumor maturation, and extended survival in experimental brain tumors in rats treated with phenylacetate. Cancer Res., 54: 2923-2927, 1994.
11. Thibault, A., Cooper, M. R., Figg, W. D., Venzon, D. J., Sartor, A. O., Tompkins, A. C., Weinberger, M. S., Headlee, D. J., McCall, N. A., Samid, D., and Myers, C. E. A Phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res., 54: 1690-1694, 1994.
12. Thibault, A., Samid, D., Cooper, M. R., Figg, W. D., Tompkins, A. C., Patronas, N., Headlee, D. U., Kohler, D. R., Venzon, D. J., and Myers, C. E. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (Phila.), 75: 2932-2938, 1995.
13. Neish, W. J. P. Phenylacetic acid as a potential therapeutic agent for the treatment of human cancer. Experientia (Basel), 27: 860-861, 1971.
14. Samid, D., Ram, Z., Hudgins, R., Shack, S., Liu, L., Walbridge, S., Oldfield, E. H., and Myers, C. E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res., 54: 891-895, 1994.
15. ra isoprenylation and phenotypic reversion. Int. J. Cancer, 63: 124-129, 1995.
16. Hudgins, W. R., Shack, S., Myers, C. E., and Samid, D. Cytostatic activity of phenylacetate and derivatives against tumor cells. Biochem. Pharmacol., 50: 1273-1279, 1995.
17. Danesi, R., Nardini, D., Basolo, F., Deltacca, M., Samid, D., and Myers, C. E. Phenylacetate inhibits protein isoprenylation and growth of the androgen-independent LNCAP prostate cancer cells transfected with the T24 Ha-RAS oncogene. Mol. Pharmacol., 49: 972-979, 1996.
18. Bates, S., and Peters, G. Cyclin D1 as a cellular proto-oncogene. Semin. Cancer Biol., 6: 73-82, 1995.
19. Pineau, T., Hudgins, W. R., Liu, L., Chenn, L. L., Sher, T., Gonzalez, F. J., and Samid, D. Activation of a human peroxisome proliforator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol., 52: 659-667, 1996.
20. Samid, D., Shack, S., and Myers, C. E. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J. Clin. Invest., 91: 2288-2295, 1993.
21. Shack, S., Miller, A., Liv, L., Prasanna, P., Thibault, A., and Samid, D. Vulnerability of multidrug-resistant tumor cells to the aromatic fatty acids phenylacetate and phenylbutyrate. Clin. Cancer Res., 2: 865-872, 1996.
22. Freedman, R. S., Bowen, J. M., Leibovitz, A., Pathak, S., Siciliano, M. J., Gallager, H. S., and Giovanella, B. C. Characterization of an ovarian carcinoma cell line. Cancer (Phila.), 42: 2352-2359, 1978.
23. Pettersson, F., Creasman, W. T., Shepherd, J. H., and Pecorelli, S. (eds.), Annual Report on the Results of Treatment in Gynecological Cancer. Stockholm, Sweden. Vol. 22, pp. 1987-1989, 1988.
24. Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer drug screening. J. Natl. Cancer Inst. (Bethesda), 82: 1107-1112, 1990.
25. Berenbaum, M. C. Criteria for analyzing interaction between biologically active agents. Adv. Cancer Res., 25: 269-335, 1981.
26. Carducci, M. A., Nelson, J. B., Chan-Tack, K. M., Ayyagari, S. R., Sweatt, W. H., Campbell, P. A., Nelson, W. G., and Simons, J. W. Phenylbutyrate induced apoptosis in human prostate cancer is more potent than phenylacetate. Clin. Cancer Res., 2: 379-387, 1996.
27. Stockhammer, G., Manley, G. T., Johnson, R., Rosenblum, M. K., Samid, D., and Lieberman, F. S. Inhibition of proliferation and induction of differentiation in meduloblastoma- and astrocytoma-derived cell lines with phenylacetate. J. Neurosurg. 83: 672-681, 1995.
28. Scambia, G., Masciullo, V., Benedetti-Panici, P., Marone, M., Ferrandina, G., Todaro, N., Ballacosa, A., Neri, G., Piffanelli, A., and Mancuso, S. Prognostic significance of Ras/p21 alterations in human ovarian cancer, Br. J. Cancer, 75: 1547-1573, 1997.
29. Oltvai, Z., Milliman, C., and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homology Bax that accelerated programmed cell death. Cell, 74: 609-619, 1993.
30. Fakhrai, H., Dorigo, O., Shawler, D. L., Ling, H., Mercola, D., Black, K. L., Royston, I., and Sobol, R. E. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA, 93: 2909-2914, 1996.
31. Gorski, G. K., Donaldson, M. H., and McMorrow, L. E. Synergistic inhibition of human rhabdomyosarcoma cells by sodium phenylacetate and tretinoin. In Vitro Cell. Dev. Biol., 29A: 189-191, 1986.
32. Esquenet, M., Swinnen, J. V., Heyns, W., and Verhoeven, G. Control of LnCaP proliferation and differentiation actions and interactions of androgens, 1-α, 25-dihydroxycholecalciferol, all-trans-retinoic acid, 9-cis-retinoic acid, and phenylacetate. Prostate, 28: 182-194, 1996.
33. Prasanna, P., Thibault, A., Liu, L., and Samid, D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem., 66: 710-716, 1996.
34. 1-phase Chinese hamster V 79-379A cells are inherently more sensitive to platinum bound to their DNA than mid-S-phase or asynchronously treated cells. Biochem. Pharmacol., 28: 1575-1580, 1979.